Skip to main content
N4 PHARMA PLC logo

N4 PHARMA PLC — Investor Relations & Filings

Ticker · N4P ISIN · GB00BYW8QM32 LEI · 213800I841D2RKMFK955 IL Professional, scientific and technical activities
Open in API
Filings indexed 840 across all filing types
Latest filing 2017-05-23 Major Shareholding Noti…
Country GB United Kingdom
Listing IL N4P

About N4 PHARMA PLC

https://n4pharma.com/

N4 Pharma PLC is a specialist pharmaceutical company focused on the development of Nuvec®, its proprietary silica nanoparticle delivery system. This platform technology is designed to enhance the cellular delivery and potency of nucleic acid-based treatments, such as vaccines and cancer therapies. The company's primary focus is on applying Nuvec® to enable advanced therapies for oncology and infectious diseases. N4 Pharma's business model involves developing and out-licensing its technology to pharmaceutical and biotechnology partners to improve the performance of new and existing drugs.

Recent filings

Filing Released Lang Actions
Holding(s) in Company
Major Shareholding Notification Classification · 1% confidence The document is explicitly labeled with "RNS Number : 9441F" and contains the header "TR-1: NOTIFICATION OF MAJOR INTEREST IN SHARES". This format is characteristic of regulatory notifications filed with a stock exchange, specifically referencing the London Stock Exchange's RNS service ("This information is provided by RNS"). The content details changes in major shareholdings (crossing thresholds) by specific entities (Abingworth LLP and Abingworth Bioventures VI LP). This falls under the category of reporting changes in significant ownership, which aligns best with the 'Major Shareholding Notification' (MRQ) definition, or as a general regulatory filing if MRQ is too specific for the provided list. However, since 'Major Shareholding Notification' (MRQ) is an explicit option and the document is a direct notification of crossing a shareholding threshold, MRQ is the most accurate classification. It is not a general announcement of a report (RPA) because it *is* the report/notification itself.
2017-05-23 English
Partial Exercise of Over-Allotment Option
Declaration of Voting Results & Voting Rights Announcements Classification · 1% confidence The document is identified by the RNS Number header and the closing statement "This information is provided by RNS The company news service from the London Stock Exchange". The content details the partial exercise of an over-allotment option following a global offering, resulting in new share issuance and an update to the total voting rights. This is a specific corporate action announcement related to financing and capital structure changes, but it is being disseminated via the RNS regulatory news service. Since the core event is a capital/financing update (raising proceeds, issuing shares), the most specific code is 'CAP' (Capital/Financing Update). However, because the document is explicitly an RNS announcement and details the resulting share capital change (which could also suggest 'SHA'), the primary nature is the financial transaction itself. Given the context of raising capital via an offering, 'CAP' is highly relevant. Since it is a formal regulatory announcement disseminated through the RNS system, and it directly relates to the issuance of shares following a financing event, 'CAP' (Capital/Financing Update) is the best fit over the more general 'SHA' (Share Issue/Capital Change) or the fallback 'RNS'. The document is not short enough to definitively be an RPA based on the 'MENU VS MEAL' rule, as it contains substantial detail about the transaction, not just a pointer to another document.
2017-05-16 English
Price Monitoring Extension
Regulatory Filings Classification · 1% confidence The document is very short (1160 characters) and appears to be a notification disseminated via the RNS (Regulatory News Service) system, indicated by the header 'RNS Number : 1856F'. The content describes a 'Price Monitoring Extension' related to an auction call period for N4 Pharma PLC, which is a specific, non-standard market operation announcement. It does not contain comprehensive financial data (like 10-K or IR), management changes (MANG), or dividend details (DIV). Since it is a specific regulatory announcement that doesn't fit into the more defined categories like DIRS, DVA, or ER, and it is a direct notification from the exchange service, the most appropriate fallback category is Regulatory Filings (RNS).
2017-05-15 English
Holding(s) in Company
Major Shareholding Notification Classification · 1% confidence The document is clearly identified by the header 'RNS Number : 1587F' and the footer 'This information is provided by RNS The company news service from the London Stock Exchange'. The content is a 'TR-1: NOTIFICATION OF MAJOR INTEREST IN SHARES', which details changes in significant share ownership (Peel Hunt LLP crossing the 'Under 10%' threshold). This directly corresponds to the definition of Major Shareholding Notification (MRQ). Although it is distributed via RNS, the specific nature of the filing (TR-1 major holding notification) makes MRQ the most precise classification over the general RNS fallback.
2017-05-15 English
Holding(s) in Company
Major Shareholding Notification Classification · 1% confidence The document is clearly identified by the header 'RNS Number : 1591F' and the footer 'This information is provided by RNS The company news service from the London Stock Exchange'. The content details a 'TR-1: NOTIFICATION OF MAJOR INTEREST IN SHARES' filed by Peel Hunt LLP regarding N4 Pharma Plc, indicating a change in shareholding that crossed the 10% threshold. This type of filing, which reports changes in significant share ownership, directly corresponds to the Major Shareholding Notification category (MRQ). Although RNS is mentioned, MRQ is a more specific classification for this type of regulatory disclosure.
2017-05-15 English
Filing of Patents and Sildenafil Update
Regulatory Filings Classification · 1% confidence The document is identified by the presence of an 'RNS Number' and the closing statement 'This information is provided by RNS The company news service from the London Stock Exchange'. RNS stands for Regulatory News Service, which is a general regulatory announcement channel, often used for immediate updates that don't fit a specific SEC form type (like 10-K or DEF 14A). The content announces patent filings, progress toward clinical trials (sildenafil, paroxetine, duloxetine), and includes commentary from the CEO. This is a corporate update announcing significant operational and intellectual property developments. Since it is a general regulatory announcement distributed via the LSE's news service and doesn't fit precisely into categories like Capital Change (SHA), Director's Dealing (DIRS), or Earnings Release (ER), the most appropriate fallback category for a general regulatory announcement is RNS.
2017-05-15 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.